Summary
ILD is a heterogeneous group of 200+ chronic lung disorders marked by inflammation and progressive scarring that cause worsening breathlessness, declining lung function, and shortened life expectancy.
Monoclonal antibodies (mAbs) are reshaping ILD care by precisely targeting inflammatory and fibrotic pathways, offering potential for greater efficacy, improved safety, and more personalized treatment versus traditional antifibrotics.
Roche’s ACTEMRA (tocilizumab), an IL-6 receptor mAb for SSc‑ILD, has demonstrated that a targeted biologic can achieve meaningful commercial traction (around USD 172 million in 2025) and disrupt antifibrotic‑dominated trea...
